The projected value of genome editing therapy market is expected to be valued at USD 0.45 billion in 2022 and is anticipated to grow at a CAGR of 18% during the forecast period 2022-2035.

The groundbreaking isolation of Hind II, the first site-specific restriction enzyme, in the 1970s marked a pivotal moment in the field of biotechnology. This monumental discovery not only represented a leap forward in scientific understanding but also laid the foundation for the manipulation of living organisms at the genomic level. This breakthrough opened up unprecedented possibilities in both basic and applied life sciences. Fast forward to the 1980s, and we witnessed another milestone with the approval by the US FDA of HUMULIN?, the world’s inaugural genetically modified medication containing human insulin. This marked a significant step towards harnessing the potential of genetic engineering for therapeutic purposes. Subsequent advancements in DNA modulation technologies, such as Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), Engineered Meganucleases (EMNs), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), have catapulted genetic engineering and genome editing to the forefront of scientific innovation.

These cutting-edge technologies empower researchers to make precise, sequence-specific modifications in various cell types and organisms, revolutionizing the way we approach biological research and medical interventions. While gene editing technologies continue to be extensively explored for fundamental research, their therapeutic potential has become a focal point for select stakeholders within the pharmaceutical and biotechnology sectors. This emphasis is partly attributed to the adoption of surrogate licensing models, providing drug developers with exclusive control over intellectual property, thereby influencing the trajectory of research and development in this domain.

Clinical trials, in particular, are focusing on infectious diseases and oncological disorders. However, noteworthy strides are being made in product candidates targeting hematological, genetic, and neurological disorders, currently in the discovery and preclinical stages. This diversified approach underscores the versatility and expansive potential of gene editing technologies in addressing a spectrum of health challenges.

The burgeoning field has attracted a substantial investment of USD 2 billion, fostering strategic partnerships and setting the stage for sustained market growth anticipated during the forecast period. As we navigate this era of unprecedented scientific advancement, the convergence of biotechnology and medicine holds promise for transformative breakthroughs in healthcare and beyond.

Research Coverage
? Key research insights on the current state and future evolution of ZFNs, TALENs, and meganucleases therapies.
? An introduction of gene editing, evolution of tools, and details on ZFNs, TALENs, and meganucleases, including their structure, mechanism, advantages, challenges, and future prospects.
? Detailed market landscape, analyzing parameters like development phase, target indication, and companies involved in ZFNs, TALENs, and meganucleases therapies.
? Eloborated profiles major players in this field, covering company overviews, drug candidates, financial information, recent developments, and future outlook.
? Details on completed and ongoing clinical studies, highlighting trial parameters, active industry players, and trial locations.
? Reviews on scientific articles on ZFNs, TALENs, and meganucleases therapies, considering publication year, therapeutic focus, top journals, and authors.
? Academic grants awarded for related projects from 2017-2021, including grant details and recipient organizations.
? Detailed partnerships in the domain until 2021, encompassing R&D agreements, mergers, acquisitions, and licensing agreements.
? Elaborated funding and investments in the field till 2021, categorizing them based on parameters such as grants, venture capital financing, and IPOs.
? Detailed analysis on patents filed/granted for ZFNs, TALENs, and meganucleases till 2021, considering patent type, issuing authority, and leading industry players.
? Elaborated list of key opinion leaders (KOLs) in the domain, evaluating their expertise based on publications, citations, clinical trial participation, affiliations, and professional network.
? A case study on CRISPR/Cas-based therapeutics in various stages of development.

Key Market Companies
? Allogene Therapeutics
? Bluebird Bio
? Cellectis
? Cytovia Therapeutics
? Iovance Therapeutics
? Precision Biosciences
? Sangamo Therapeutics